The clinical, pathological, and genetic features of familial isolated pituitary adenomas

被引:107
作者
Beckers, Albert [1 ]
Daly, Adrian F. [1 ]
机构
[1] Univ Liege, CHU Liege, Domaine Univ Sart Tilman, Dept Endocrinol, B-4000 Liege, Belgium
关键词
D O I
10.1530/EJE-07-0348
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Pituitary adenomas occur in a familial setting in multiple endocrine neoplasia type 1 (MEN1) and Carney's complex (CNC), which occur due to mutations in the genes MEN1 and PRKAR1A respectively. Isolated familial somatotropinoma (IFS) is also a well-described clinical syndrome retated only to patients with acrogigantism. Pituitary adenomas of all types - not limited to IFS - can occur in a familial setting in the absence of MEN1 and CNC; this phenotype is tcrmed familial isolated pituitary adenomas (FIPA). Over the past 7 years, we have described over 90 FIPA kindreds. In FIPA, both homogeneous and heterogeneous pituitary adenoma phenotypes can occur within families; virtually all FIPA kindreds contain at least one prolactinoma or somatotropinoma. FIPA differs from MEN1 in terms of a lower proportion of prolactinomas and more frequent somatotropinomas in the FIPA cohort. Patients with FIPA are significantly younger at diagnosis and have significantly larger pituitary adenomas than matched sporadic pituitary adenoma counterparts. A minority of FIPA families overall (15%) exhibit mutations in the aryl hydrocarbon receptor-interacting protein (AIP) gene; AIP mutations are present in only half of IFS kindreds occurring as part of the FIPA cohort. In families with AIP mutations, pituitary adenomas have a penetrance of over 50%. AIP mutations are extremely rare in patients with sporadic pituitary adenomas. This review deals with pituitary adenomas that occur in a familial setting, describes in detail the clinical, pathological, and genetic features of FIPA, and addresses aspects of the clinical approach to FIPA families with and without AIP mutations.
引用
收藏
页码:371 / 382
页数:12
相关论文
共 70 条
[1]   Acromegaly in a family without a mutation in the menin gene [J].
Ackermann, F ;
Krohn, K ;
Windgassen, M ;
Buchfelder, M ;
Fahlbusch, R ;
Paschke, R .
EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 1999, 107 (01) :93-96
[2]   Molecular pathology of the MEN1 gene [J].
Agarwal, SK ;
Burns, L ;
Sukhodolets, KE ;
Kennedy, PA ;
Obungu, VH ;
Hickman, AB ;
Mullendore, ME ;
Whitten, I ;
Skarulis, MC ;
Simonds, WF ;
Mateo, C ;
Crabtree, JS ;
Scacheri, PC ;
Ji, YM ;
Novotny, EA ;
Garrett-Beal, L ;
Ward, JM ;
Libutti, SK ;
Alexander, HR ;
Cerrato, A ;
Parisi, MJ ;
Santa Anna-A, S ;
Oliver, B ;
Chandrasekharappa, SC ;
Collins, FS ;
Spiegel, AM ;
Marx, SJ .
GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR DISEASE: MOLECULAR AND CELL BIOLOGICAL ASPECTS, 2004, 1014 :189-198
[3]   Genetics and proteomics of pituitary tumors [J].
Sylvia L. Asa ;
Shereen Ezzat .
Endocrine, 2005, 28 (1) :43-47
[4]  
BAIKOS SA, 2006, PITUITARY, V9, P203
[5]   Mutations in the aryl hydrocarbon receptor interacting protein gene are not highly prevalent among subjects with sporadic pituitary adenomas [J].
Barlier, Anne ;
Vanbellinghen, Jean-Francois ;
Daly, Adrian F. ;
Silvy, Monique ;
Jaffrain-Rea, Marie-Lise ;
Trouillas, Jacqueline ;
Tamagno, Gianluca ;
Cazabat, Laure ;
Bours, Vincent ;
Brue, Thierry ;
Enjalbert, Alain ;
Beckers, Albert .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (05) :1952-1955
[6]  
Beckers A, 2004, J INTERN MED, V255, P698
[7]   Binding of aryl hydrocarbon receptor (AhR) to AhR-interacting protein - The role of hsp90 [J].
Bell, DR ;
Poland, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (46) :36407-36414
[8]   FAMILIAL PROLACTINOMA [J].
BEREZIN, M ;
KARASIK, A .
CLINICAL ENDOCRINOLOGY, 1995, 42 (05) :483-486
[9]   Predictors and rates of treatment-resistant tumor growth in acromegaly [J].
Besser, GM ;
Burman, P ;
Daly, AF .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2005, 153 (02) :187-193
[10]  
Betea D, 2000, ANN ENDOCRINOL-PARIS, V61, P214